Which of the Blockbuster Drugs on the Autoimmune Drug Market Will Show the Glory that Humira Had?(2)

Review of the drugs:

Enbrel and Remicade have begun to suffer impacts of generic drugs, with market shares largely reducing.

As the third anti-TNFα monoclonal antibody marketed and the first fully human antibody, Humira has taken 14 clinical indications upon its advantages in clinical efficacy (the above two separately have 5 and 8) and advanced triumphantly on the market, to become a king.

FDA has approved the two biosimilars of Humira: Amgen’s Amjevita (adalimumab-atto, September 23, 2016) and Ogivri (trastuzumab-dkst, August 25, 2017), however, AbbVie managed to shut them out by reaching a settlement with Amgen and accusing Boehringer Ingelheim of patent infringement, therefore, Humira will still be unshakeable in the next years.

Although "envied" by other drugs, Humira makes a "a wry smile": the sunset is so beautiful, but that evening (of Humira) is on the way!

Cimzia and Simponi were marketed later than the above three monoclonal antibodies, and their sales are expected to continue to rise to reach USD 2 billion before patent expiration, however, the overall market of anti-TNFα monoclonal antibodies becomes increasingly saturated and tumultuous due to impacts of generic drugs and competition from latecomers, and is difficult to continue the peak of the above 3 all exceeding USD 10 billion sales.

Related reading: Which of the Blockbuster Drugs on the Autoimmune Drug Market Will Show the Glory that Humira Had?(1)

Register as Visitor to CPhI China 2018!